Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy by Sprave, Tanja et al.








Randomized phase II trial evaluating pain response in patients with spinal
metastases following stereotactic body radiotherapy versus
three-dimensional conformal radiotherapy
Sprave, Tanja; Verma, Vivek; Förster, Robert; Schlampp, Ingmar; Bruckner, Thomas; Bostel, Tilman;
Welte, Stefan Ezechiel; Tonndorf-Martini, Eric; Nicolay, Nils Henrik; Debus, Jürgen; Rief, Harald
Abstract: BACKGROUND To report the primary endpoint of a randomized trial comparing pain re-
sponse following palliative stereotactic body radiation therapy (SBRT) versus conventionally-fractionated
3D-conformal radiotherapy (3DCRT) for previously untreated spinal metastases. METHODS Fifty-five
patients with histologically/radiologically confirmed painful spinal metastases were analyzed in this single-
institutional, non-blinded, randomized explorative trial. Participants were randomly assigned (1:1) to
receive single-fraction SBRT (24 Gy) or 3DCRT (30 Gy in 10 fractions). The primary endpoint was
pain relief of >2 points on the visual analog scale (VAS) measured within the irradiated region at 3
months following radiotherapy completion. Other recorded parameters included pain response (per In-
ternational Bone Consensus response definitions), use of concurrent medications and opioid usage (oral
morphine equivalent dose, OMED). All parameters were assessed at baseline and at three and six months
after RT. Intention-to-treat analysis was applied. This trial is registered with ClinicalTrials.gov, number
NCT02358720. FINDINGS Despite no significant differences for VAS at 3 months between groups (p =
0.13), pain values decreased faster within this time period in the SBRT arm (p = 0.01). At 6 months
following RT, significantly lower VAS values were reported in the SBRT group (p = 0.002). There were no
differences in OMED consumption at 3 (p = 0.761) and 6 months (p = 0.174). There was a trend toward
improved pain response in the SBRT arm at 3 months (p = 0.057), but significantly so after 6 months
(p = 0.003). No patient in the SBRT group experienced grade ￿3 toxicities according to the Common
Terminology Criteria for Adverse Events v.4.03. CONCLUSIONS This randomized trial demonstrates
the utility of palliative SBRT for spinal metastases, which was associated with a quicker and improved
pain response. Larger ongoing randomized studies will assist in further addressing these endpoints.
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a b s t r a c t
Background: To report the primary endpoint of a randomized trial comparing pain response following
palliative stereotactic body radiation therapy (SBRT) versus conventionally-fractionated 3D-conformal
radiotherapy (3DCRT) for previously untreated spinal metastases.
Methods: Fifty-five patients with histologically/radiologically confirmed painful spinal metastases were
analyzed in this single-institutional, non-blinded, randomized explorative trial. Participants were ran-
domly assigned (1:1) to receive single-fraction SBRT (24 Gy) or 3DCRT (30 Gy in 10 fractions). The pri-
mary endpoint was pain relief of >2 points on the visual analog scale (VAS) measured within the
irradiated region at 3 months following radiotherapy completion. Other recorded parameters included
pain response (per International Bone Consensus response definitions), use of concurrent medications
and opioid usage (oral morphine equivalent dose, OMED). All parameters were assessed at baseline
and at three and six months after RT. Intention-to-treat analysis was applied. This trial is registered with
ClinicalTrials.gov, number NCT02358720.
Findings: Despite no significant differences for VAS at 3 months between groups (p = 0.13), pain values
decreased faster within this time period in the SBRT arm (p = 0.01). At 6 months following RT, signifi-
cantly lower VAS values were reported in the SBRT group (p = 0.002). There were no differences in
OMED consumption at 3 (p = 0.761) and 6 months (p = 0.174). There was a trend toward improved pain
response in the SBRT arm at 3 months (p = 0.057), but significantly so after 6 months (p = 0.003). No
patient in the SBRT group experienced grade 3 toxicities according to the Common Terminology
Criteria for Adverse Events v.4.03.
Conclusions: This randomized trial demonstrates the utility of palliative SBRT for spinal metastases,
which was associated with a quicker and improved pain response. Larger ongoing randomized studies
will assist in further addressing these endpoints.
 2018 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 128 (2018) 274–282. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Approximately one third of cancer patients will develop bone
metastases, approximately two thirds of which involve the verte-
bral column, most commonly at the thoracic and lumbar levels
[1,2]. Conventionally fractionated 3D-conformal radiotherapy
(3DCRT) is a well-recognized palliative treatment for painful bone
metastases [3–14]. Comprehensive meta-analyses by Sze et al. and
Wu et al. have provided consistent data regarding pain response
after conventional external beam radiotherapy [13,14]. The overall
(pain) response (OR) was up to 60% and complete (pain) response
(CR) around one third [13,14]. A systematic review by Chow et al.
yielded similar results in respect to OR, but lower CR rates of
approximately 23% [3].
It has long been questioned whether an increase in radiation
dose may lead to increased pain control while maintaining few
toxicities. Although 3DCRT is limited in its capacity to dose-
escalate owing to spinal cord dose constraints, stereotactic body
radiation therapy (SBRT) is a highly conformal technique that does
allow for safe dose-escalation [15–19]. These notions have been
supported by phase I–II data demonstrating a clinical benefit of
SBRT in the primary or salvage treatment of stable spinal lesions
[20]. Phase II results of the RTOG 0631 study showed stereotactic
radiosurgery to be feasible and accurate [21]. The latter is the basis
for the currently ongoing RTOG 0631 phase III assessment, which
aims to compare pain response and quality of life (QoL) between
SBRT (single dose of 16 Gy) and EBRT (external beam radiotherapy)
(single dose of 8 Gy).
To date, no randomized trials are available comparing SBRTwith
conventional3DCRT in termsofpain relief. Furthermore, the interac-
tion between ablative doses and pain response remains unclear. The
aimof this randomized trialwas to analyze pain response after high-
dose SBRT versus conventional 3DCRT for this patient population.
Materials and methods
Subjects, recruitment strategy, and eligibility for enrollment
From November 2014 to March 2017, 60 patients with histolog-
ically confirmed cancer and painful bone metastases of the thoracic
or lumbar vertebral column were randomized in both arms: high-
dose single-fraction SBRT (24 Gy) versus standard fractioned 3DRT
(10  3 Gy).
Inclusion criteria were ages 18–80, a Karnofsky performance
score [22] 70, ability to provide written informed consent, a max-
imum of two irradiated vertebral bodies per region, a maximum of
two different vertebral regions affected, and tumor distance >3
mm to the spinal cord. Exclusion criteria were subjects with signif-
icant neurological or psychiatric disorders precluding informed
consent, previous RT to the given irradiation site, contraindications
for MRI, multiple myeloma or lymphoma histology, or involvement
of the cervical spine.
In total, five patients were duly excluded. Four patients in the
SBRT arm had an insufficient distance between tumor and spinal
cord. One participant from the control arm was excluded because
of the confirmed diagnosis of multiple myeloma after randomiza-
tion. 55 patients met the inclusion/exclusion criteria and were
enrolled into the trial (Fig. 1).
The randomized trial, registered on clinicaltrials.gov
(NCT02358720), was approved by the Heidelberg University Inde-
pendent Ethics Committee (Nr. S-431/2013). Additionally, approval
was given from the German Federal Office of Radiation Protection
(BfS).
Design, randomized allocation, and procedures
This was a randomized, single-institutional, explorative study
with the intention to compare pain response after high-dose single
fraction SBRT versus conventional 3DCRT in patients with painful
untreated spinal bone metastases. Details of the study design have
been published previously [23]. A block randomization approach
(block size of 6) was used to ensure that the two groups were
balanced.
Two different techniques were evaluated on a 1:1 basis accord-
ing to the randomization list: high-dose, single-fraction (24 Gy to
the 80% isodose line) SBRT versus 30 Gy in 10 fractions of conven-
tional radiotherapy.
The randomization procedure was carried out by a central
office. Prior to their enrollment into the study, patients underwent
staging of the vertebral column in connection with planning com-
puted tomography (CT) and MRI to measure the spinal cord dimen-
sion. The prerequisite for participation in the study was the
exclusion of spinal cord compression, along with a sufficient dis-
tance (>3 mm) between the metastasized vertebral body and
spinal cord on MRI.
The primary endpoint-related parameters were measured at the
start of RT (t0), at the end of RT (t1), 3 months post-RT (t2), and 6
months post-RT (t3). These parameters included the following:
documentation of pain according to the Visual Analog Scale
(VAS), neuropathic pain, OMED [5], and as well as individual
patient-specific data such as use of concurrent medications.
During therapy, treating physicians documented each of these
parameters; subsequently, patients continued complete documen-
tation by means of pain diaries. VAS (collated as weekly mean val-
ues) and concurrent medication usage were documented daily for
3 months, and once after 6 months. In addition, use of basic pain
medications and other concurrent medications (or medication
changes) were continuously recorded from the start of RT to 6
months. In addition to patient-reported neuropathic pain use, opi-
oid analgesic usage was converted into an oral morphine equiva-
lent dose (OMED), and any non-opioid analgesics were also
recorded.
Patient records were collected by the authors. The evaluation
included all recorded data up to the 6-month follow-up interval.
The baseline data of the patient characteristics are presented in
summary (Table 1).
Assessment of the primary endpoints
The primary endpoint of this randomized, single-institutional,
phase II trial was pain response after high-dose single-fraction
SBRT versus conventional 3DCRT in patients with painful, previ-
ously untreated spinal metastases. The primary endpoint was
defined as pain relief >2 points according to the visual analog scale
(VAS) measured at the irradiated region three months after RT (t2).
The pain response was assessed according to the International
Bone Consensus response categories by Chow et al. [5] as complete
response (CR), partial response (PR), pain progression (PP), and
intermediate pain (IP) at 3 and 6 months after RT. Complete
response (CR) was defined as VAS = 0 after 3 months and partial
response (PR) as an improvement by at least two score points after
3 and 6 months. CR was defined as VAS = 0 at the treated site with
no concurrent increase in analgesic intake (stable or reducing anal-
gesics in daily OMED). PR was defined as pain reduction of 2 or
more at the treated site without analgesic increase, or analgesic
reduction of 25% or more from baseline without an increase in
pain. PP was defined as increase in pain score of 2 or more above
baseline at the treated site with stable OMED, or an increase of
25% or more in OMED compared with baseline with the pain score
stable or 1 point above baseline. Any response not covered by the
complete response, partial response, or pain progression defini-
tions was called ‘‘intermediate pain”. Responders were defined as
having CR or PR, non-responders as having PP or IP.
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Radiotherapy
CT simulation was carried out with custom immobilization
using Aquaplast head masks, vacuum mattresses, and/or Wing-
step arm abduction framework. Regarding target delineation
(performed with MRI co-registration), each vertebral body was
divided into 3 sectors. Sectors I and III represent the lateral area
of the vertebral body with the respective ipsilateral left or right
pedicle, lamina, and transverse process. Sector II represents the
middle third of the vertebral body with the spinous process. The
gross tumor volume (GTV) was defined as the visible lesion with
a 3 mm safety margin. The CTV included the affected vertebral
body sector/s plus any unaffected sector. The PTV was defined by
adding a 5 mm safety margin to the CTV. The volume (PRV) of
the planning organ at risk (OAR), in this case the spinal cord, was
a 3 mm expansion of this structure. The margin to the spinal cord
was never less than 3 mm. The PTV never overlapped with the
spinal cord or cauda equina.
In the SBRT cohort, the planning target volume (PTV) was to be
covered by the 80% isodose line, and a single fraction of 24 Gy was
prescribed to this isodose line. OAR tolerance doses were per the
RTOG 0631 trial [24]. SBRT was delivered by an Elekta Versa HD
linac employing MLC Agility leafs and a width of 5 mm at isocenter
distance, with full dual VMAT arcs (178–182 ccw, 182–178 cw).
Treatment was delivered using one of three possible techniques.
VMAT with 6 MV flattering filter free (FFF) beams was delivered
at a dose rate of 1400 MU/min. TomoTherapy (Accuray Inc., Madi-
son, WI) was another technique; image guidance thereof com-
prised of pre-treatment megavoltage CT, followed by delivery of
12 Gy, followed by repeat megavoltage CT, and delivery of the
remaining 12 Gy. The third technique was step-and-shoot IMRT
with flattened 6 MV photons. Dose delivery and dosimetric accu-
racy of each plan were assessed by patient specific quality assur-
ance (QA) using 3D-reconstucted dose measurement with the
OD1500 2D-detector array inside the OCTAVIUS 4D rotational
phantom.
For the 3DCRT arm, treatment was performed as irradiation of
the involved vertebral body as well those immediately above and
below to a total dose of 30 Gy in 10 fractions, most commonly
delivered with 3 or 4 anteroposterior/posteroanterior beams. The
same tolerance doses of the organs at risk as in the RTOG 0631
study are used [24]. Position verification was carried out weekly
before radiotherapy by kilovoltage cone-beam CT (kV-CBCT)
and before each fraction by orthogonal portal images being com-
pared with digitally reconstructed radiographs (DRR) from the
planning CT.
Statistical analysis
Owing to the exploratory nature of this study, a complete
power calculation was not possible; however, with 30 patients
in each group, it was possible to detect a standardized mean-
value effect of 0.8 with 80% power at a significance level of
0.05.
All variables were analyzed descriptively by tabulation of the
measures of the empirical distributions. According to the scale
level of the variables, means and standard deviations or absolute
and relative frequencies, respectively, were reported. Addition-
ally, for variables with longitudinal measurements, the time
courses of individual patients and are summarized by treatment
groups. Descriptive p-values of the corresponding statistical tests
comparing the treatment groups were given. The VAS was
adjusted for concurrent medication. Analysis of covariance
(ANOVA) with repeated measurements, with treatment group as
a factor, and pain medication as a covariate, were done. The Wil-
coxon signed-rank test was used to detect possible differences
between groups after 3 and 6 months. Graphical visualization
includes boxplots and mean course over time. Finally, we com-
pared the groups for overall and bone survival, using Kaplan–
Meier estimates and log-rank tests. Overall survival (OS) was
defined as time from randomization until death, or censored at
last contact.
Fig. 1. Trial profile.
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All statistical analyses were done using SAS software Version
9.4 or higher (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics were balanced between the two treat-
ment arms (Table 1). The mean follow-up was 8.1 months for both
groups. At baseline, NSAIDs were taken by 55.6% (n = 15) in the
SBRT group, and opioid analgesics by 40.7% (n = 7). Corresponding
numbers in the 3DCRT group were 53.6% (n = 15) and 35.7% (n =
10), respectively.
All surviving patients completed every required question-
naire. Four patients (14.8%) in the SBRT group died within 12
weeks of RT, and another 4 patients (14.8%) died of disease
between 12 and 24 weeks. In the 3DCRT arm, 5 patients
(17.9%) died within 3 months, and another 3 patients (10.7%)
died between 3 and 6 months of RT (Fig. 1). No differences were
present between groups in terms of OS (p = 0.659) and bone sur-
vival (BS) (p = 0.660) (Figs. 2–3). The mean OS was 7.9 months
for both groups.
There were no significant differences in the pattern of recorded
OMED consumption between treatment arms within 3 months (t2)
(p = 0.761) and 6 months (t3) after RT (p = 0.174) (Fig. 4).
Twenty-three (85%) participants in the SBRT group and 23
(82%) in the 3DCRT group were assessable for pain response at
3 months. Nineteen (70%) patients in the SBRT arm and 20
(71%) in the 3DCRT arm were assessable for pain relief response
at 6 months. The measurement repetition for variance analysis
showed no significant difference in final VAS at 3 months (t2)
(p = 0.13). However, a difference in time to subjective pain relief
between both groups during the first 3 months was noted (p <
0.001, Fig. 5). The VAS value decreased faster in the SBRT arm
(p = 0.01, Fig. 6). At 6 months (t3) following RT, significantly
lower VAS values were reported in the SBRT group (p = 0.002).
No differences were discerned between groups in terms of neu-
ropathic pain at baseline, as well as 3 and 6 months following RT
(Table 2).
Pain response is given in Table 3. At 3 months, there was a trend
(p = 0.057) toward improved pain response in the SBRT group, as
43.5% therein experienced a CR, as compared to 17.4% in the 3DCRT
group. IP was present in 21.7% of the SBRT cohort, as compared to
52.2% in the 3DCRT arm. At 6 months, 52.6% of the SBRT arm
achieved CR (10.0% for 3DCRT), with IP figures of 15.8% versus
65.0%, respectively (p = 0.003). At this time period, 73.7% of the
SBRT patients were categorized as responders, as compared to just
35.0% of those undergoing 3DCRT (p = 0.015).
RT was altogether tolerated well. No patient in the SBRT group
experienced grade 3 acute or late toxicities according to the Com-
mon Terminology Criteria for Adverse Events (v.4.03). In the SBRT
group, the most common acute side effect was fatigue (two cases
Table 1
Demographics.
SBRT group n = 27 3DCRT group n = 28 p-Value
n % n %
Age (years)
Mean (SD) 61 (8,2) 63,9 (10,8) 0,225
Gender
Male 15 55,6 13 46,4 0,499
Female 12 44,4 15 53,6
Weight (kg, SD) 76 (19,2) 78,2 (16,4)
Height (cm, SD) 171,1 (8,5) 172,3 (8,7)
Body mass index (BMI)
Mean (SD) 25,8 (5,8) 26,5 (5,7) 0,899
Primary site
Lung cancer 9 33,3 10 35,7
Breast cancer 7 26,3 10 35,7
Renal cancer 2 7,4 2 7,1
Other 9 33,3 6 21,4
Localization metastases 0,317
Thoracic 14 51,9 19 67,9
Lumbar 13 48,1 8 28,6
Number metastases 0,301
1 metastase 24 88,9 22 78,6
2 metastases 3 11,1 6 21,4
Distant metastases at baseline
Visceral 12 44,4 14 51,9 0,586
Lung 11 40,7 4 14,8 0,033
Brain 7 25,9 3 11,1 0,161
Tissue 5 18,5 4 14,8 0,715
Hormonetherapy 6 22,2 8 28,6 0,589
Immunotherapy 8 29,6 8 28,6 0,931
Chemotherapy 11 40,7 13 46,4 0,671
Surgery 8 29,6 10 35,7 0,631
Neurological deficit at baseline 0 0 1 3,6 0,322
Bisphosphonate at baseline 11 40,7 13 46,4 0,671
Orthopedic corset at baseline 3 11,1 6 21,4 0,301
Medication at baseline
Sleeping medication 1 3,7 1 3,6 0,979
Psychiatric medication 3 11,1 5 17,9 0,478
Opiate 11 40,7 10 35,7 0,701
NSAID 15 55,6 15 53,6 0,883
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of grade 2, three cases of grade 1). One patient developed grade 1
dermatitis and another developed grade 1 dysphagia; two patients
reported in-field pain flares for the initial 1–2 days. In the 3DCRT
group, the most common acute side effect was fatigue (two cases
of grade 2, five cases of grade 1). Five participants had grade 1 der-
matitis, three patients had dysphagia (one of which was grade 2),
and one patient reported grade 2 emesis (Table 4). No cases of
radiation-related myelopathy or cauda equina injury occurred
(Table 5).
Discussion
It is imperative to provide randomized evidence supporting the
utility of advanced technologies in the palliative setting. This study
compared pain responses between high-dose SBRT versus standard
3DCRT in the palliative setting for untreated spinal metastases
without spinal cord compression. It was demonstrated that
single-fraction SBRT reduced pain levels faster during the 3 months
following RT (p < 0.001) and led to improved pain scores.
Fig. 2. Overall survival of both arms.
Fig. 3. Bone survival of both arms.
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The hypothesis that ablative dosing leads to improved tumor
control is not new. The application of higher biological doses was
preferred for radioresistant tumors, those previously irradiated,
and oligometastatic disease [9,16,25]. Experiences with single-
fraction SBRT (24 Gy) is limited to a few datasets. Gerszten et al.
illustrated its safety and efficiency using the CyberKnife technique
in patients with advanced melanoma [25]. In this study, 23 of 28
consecutive patients had been previously irradiated at the involved
spine level. The median follow-up was 13 months, and long-term
improvement in pain relief was reported in 96% of patients (n =
27). The initial and post-treatment pain value was measured on a
ten-point scale. Changes in analgesic dosages were not specified
in detail [25].
The prospective non-randomized study by Nguyen and col-
leagues reported CRs after 3 and 6 months in 48.7% and 52.8% of
48 evaluable renal carcinoma patients [26]. The median follow
up was 13.1 months, although only 8 metastases were treated with
24 Gy. Nevertheless, these results are comparable to our CR rates at
3 and 6 months with 43.5% and 52.6%. Another prospective non-
randomized study demonstrated actuarial local control rates of
91.2% at 1 year in patients without prior radiation [27]. Like the
prior study, a minority of patient received the same dose as in this
trial, and no information was given regarding the pain response
[27]. Nevertheless, these numbers line up well with another inves-
tigation displaying 90% actuarial local control in 93 patients with
103 spinal lesions. Although most patients in that study received
Fig. 4. VAS-value in both groups during 12 weeks after end of the radiotherapy.
Fig. 5. OMED consumption in both groups during 12 weeks after end of the radiotherapy.
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the same dosage as this trial, no information about the pain palli-
ation was given [16]. Lastly, as this and most studies cannot com-
pletely address late toxicities, Moussazadeh et al. reported
excellent toxicity profiles in highly selected survivors with a med-
ian follow up of 6.1 years [28].
The retrospective study by Jhaveri et al. investigated a dose–re-
sponse relationship for time to pain relief in 18 renal cancer
patients with 24 various bone lesions [29]. Two hypofractionated
schedules were used 5  8 Gy and 3  8 Gy. The median follow
up was 38 weeks. Pain relief was recorded in 78% of all partici-
pants. Whereby the pain relief was quicker and more durable in
patient cohort treated with BED >/= 85 Gy. Only 14 patients were
treated with spine lesions [30]. Nevertheless these results are in
many respects comparable to ours. We achieved a similar respon-
der rate of 73.7% after 6 months. In contrast, our study included
patients with radiosensitive and radioresistant primary site. A dif-
ferent pain response of the various cancer could distort the results.
Similar with our results, SBRT had no effect on changes in concomi-
tant analgesic consumption [29].
The preexisting pathological fracture rate in our study was 29%.
The incidence of new pathological fractures at 3 and 6 months
following SBRT in our trial was 8.7% (n = 2) and 27.8% (n = 5)
respectively. A systematic review by Faruqi et al. discerned risk
factors for VCF after high dose SBRT, such as lytic lesions, preexist-
ing VCF, and higher dose per fraction [30]. These factors were also
Fig. 6. OMED and VAS of both groups at measured points.
Table 2
Change in VAS-value, neuropathic pain and OMED.
SBRT group n = 27 3DCRT group n = 28
OMED n Mean SD n Mean SD p-Value
Baseline (t0) 27 21.7 46.3 28 22.1 40.4 0.983
RT completed (t1) 27 23.1 46.3 27 20.7 39.3 0.825
After 3 months (t2) 23 20 54.6 23 18.7 38.1 0.761
After 6 months (t3) 19 13.4 41.5 20 27 43.5 0.174
Visual analog scale
Baseline (t0) 27 38.7 26.2 28 46.4 22.2 0.253
RT completed (t1) 27 37.8 27 27 31.1 20.7 0.409
After 3 months (t2) 23 16.3 20.7 23 26.1 21.4 0.077
After 6 months (t3) 19 13.7 25 20 35 21.4 0.0024
Neuropathic pain
Baseline (t0) 27 0.1 0.3 28 0 0.2 0.549
RT completed (t1) 27 0 0.2 27 0 0.2 1.000
After 3 months (t2) 23 0 0 23 0 0.2 0.339
After 6 months (t3) 19 0.1 0.2 20 0.1 0.2 1.000
Table 3
Response according to Brief Pain Inventory score at 3 and 6 months in the
per-protocol cohort.
Intervention
group n = 27
Control group
n = 28
After 3 months n % n % p-Value
CR 10 43,5 4 17,4 0,0568
PR 6 26,1 7 30,43
PP 2 8,7 0 0
IP 5 21,7 12 52,2
Responders 16 69,6 11 47,8 0,1343
Non-responders 7 30,4 12 52,2
After 6 months
CR 10 52,6 2 10 0,0034
PR 4 21,1 5 25
PP 2 10,5 0 0
IP 3 15,8 13 65
Responders 14 73,7 7 35 0,0154
Non-responders 5 26,3 13 65
Table 4
Acute side effects of both groups.
Intervention
group n = 27
Control group n = 28
Grad 1 Grad 2 Grad 1 Grad 2
Dysphagia 1 0 2 1
Emesis 0 0 0 1
Fatigue 3 2 5 2
Radiodermatitis 1 0 5 0
280 Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus
individually identified by other authors; VCF rates in those studies
varied between 7% and 39% [31–35]. Our study showed a moderate
pathological fracture rate in the SBRT arm, although the small sam-
ple sizes may have influenced this figure. No pathological fractures
in either group required salvage surgical intervention.
There are a few limitations of this study worth mentioning, in
addition to the aforementioned small sample sizes, the single-
center nature, and shorter follow-up. First, studies of palliation
encompass inherently heterogeneous patients, and the effect on
subgroups cannot be analyzed. This also makes the results difficult
to extrapolate to other work, along with the fact that the particular
assessment methods (e.g., VAS) and frequencies thereof may differ
from other work, thus also limiting generalizability.
Second, the Chow criteria recommend that patients with a pain
level ofminimum2 (or rather 50/100)VAS be included in clinical tri-
als.We included a total of 11 patientswith a VAS <20/100,which is a
constraint. This criteria also endorse utilization of the worst pain
score over the previous 3 days, rather than the weekly mean values
measured herein; these may also limit applicability. Third, steroid
doses were not accounted for, which may be associated with pain
levels andwhether patients experienced ‘‘pain flares”. Lastly, partic-
ular reasons for opioid utilization as well as subjective response of
pain relief are inherently difficult to evaluate and are known limita-
tions of any palliative study despite the prospective nature.
Salient points from our results indicate that ablative dosing to
vertebral metastases may offer clear advantages in terms of dur-
able pain response and rapidity of such. Although 3DCRT remains
the standard of care, and economic considerations of advanced
technologies for palliation remain a concern. The currently closed
phase III RTOG 0631 study and the Canadian Cancer Trial Group
SC24 phase II/III study (NCT02512965) have implications on the
standard treatment well as its perceived cost-effectiveness.
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Research in context
Evidence before this study
Narrative literature overview using the terms ‘‘SBRT”, ‘‘spinal
metastases” resulted in various single-arm prospective and retro-
spective work, which are summarized in the study protocol.
Added value of this study
This study compared the pain response between high-dose
single-fraction SBRT (24 Gy) versus conventionally fractionated
3DCRT (30 Gy in 10 fractions) for palliative management in
untreated spinal metastases without cord compression. SBRT
reduced pain levels faster during the initial 3 months after RT. Dur-
able pain relief was achieved to a greater degree at 6 months in the
SBRT group. There was no significant difference in the pattern of
recorded OMED consumption between treatment arms at 3 and
6 months after RT.
Implications of available evidence
SBRT may offer quicker and more durable pain relief over a 6-
month time period following therapy. SBRT has clear potential as
a novel treatment approach in these patients.
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